Cytokinetics (CYTK) Stock Price, News & Analysis

Company Overview

Cytokinetics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, that focuses on the discovery and development of muscle-directed therapies. Founded in 1997, Cytokinetics applies its expertise in muscle biology to address serious diseases of cardiac and skeletal muscle dysfunction. The company’s research platform centers on small molecule therapeutics that modulate muscle contractility in conditions with high unmet medical need.

The company’s lead cardiac muscle activator, omecamtiv mecarbil, is being developed in collaboration with Amgen for patients with chronic heart failure. In addition, Cytokinetics is advancing several skeletal muscle programs, including reldesemtiv, a fast skeletal muscle activator for neuromuscular disorders such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Aficamten, a cardiac myosin inhibitor in partnership with Astellas, is under investigation for hypertrophic cardiomyopathy (HCM), underscoring the company’s strategy of targeting myosin-driven disease pathways.

Over its history, Cytokinetics has established strategic alliances and global collaborations to support clinical development and commercialization. The company’s operations span North America, Europe and Asia, with clinical trial sites and research collaborations in multiple regions. This geographic reach enables Cytokinetics to explore therapeutic applications of its muscle biology platform across diverse patient populations.

Under the leadership of President and Chief Executive Officer Robert I. Blum, Cytokinetics continues to expand its pipeline and invest in early discovery. The management team combines scientific, clinical and regulatory expertise to advance muscle-directed candidates through late-stage trials. With a focus on integrating translational science and rigorous clinical investigation, the company aims to address progressive muscle diseases that currently have limited treatment options.

Key Stats

• Today's Range: $36.91 to $39.47
• 50-Day Range: $29.84 to $38.89
• 52-Week Range: $29.31 to $61.38
• Volume: 1.37 million shs
• Average Volume: 1.53 million shs
• Market Capitalization: $4.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $70.92
• Consensus Rating: Moderate Buy

Cytokinetics Stock Analysis - MarketRank™

Cytokinetics scored higher than 81% of companies evaluated by MarketBeat, and ranked 209th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cytokinetics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cytokinetics are expected to decrease in the coming year, from ($5.24) to ($5.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytokinetics is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytokinetics is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.86% of the float of Cytokinetics has been sold short.

Short Interest Ratio / Days to Cover

Cytokinetics has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Cytokinetics has recently increased by 7.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytokinetics does not currently pay a dividend.

Dividend Growth

Cytokinetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

12.86% of the float of Cytokinetics has been sold short.

Short Interest Ratio / Days to Cover

Cytokinetics has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Cytokinetics has recently increased by 7.21%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.74

News Sentiment

Cytokinetics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Cytokinetics this week, compared to 10 articles on an average week.

Search Interest

3 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,217,761.00 in company stock.

Percentage Held by Insiders

Only 2.70% of the stock of Cytokinetics is held by insiders.

CYTK Stock Analysis - Frequently Asked Questions

How have CYTK shares performed this year?

Cytokinetics' stock was trading at $47.04 on January 1st, 2025. Since then, CYTK stock has decreased by 20.9% and is now trading at $37.23.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings data on Tuesday, May, 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.41) by $0.05. Cytokinetics's revenue was up 89.1% on a year-over-year basis.
Read the conference call transcript.

Who are Cytokinetics' major shareholders?

Top institutional shareholders of Cytokinetics include E. Ohman J or Asset Management AB (0.34%), Mirador Capital Partners LP (0.12%), State of Alaska Department of Revenue (0.01%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, John T Henderson, Andrew Callos, Edward M Md Kaye, Wendall Wierenga, Muna Bhanji, B Lynne Parshall, Robert Wong and Robert Arthur Harrington.
View institutional ownership trends.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Adobe (ADBE) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYTK
• CIK: 1061983
• Web: www.cytokinetics.com
• Phone: (650) 624-3000
• Fax: 650-624-3010
• Employees: 250
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Cytokinetics: $70.92
• High Price Target: $120.00
• Low Price Target: $41.00
• Potential Upside/Downside: +89.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$589.53 million
• Net Margins: -3,201.47%
• Pretax Margin: -3,201.47%
• Return on Equity: N/A
• Return on Assets: -43.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.99
• Quick Ratio: 5.99

Sales & Book Value

• Annual Sales: $18.47 million
• Price / Sales: 241.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.15) per share
• Price / Book: -32.49

Miscellaneous

• Outstanding Shares: 119,430,000
• Free Float: 116,202,000
• Market Cap: $4.46 billion
• Optionable: Optionable
• Beta: 0.59